| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Carlota Menéndez-Pérez, Rafael Rivas-Santisteban, Eva Del Valle, Jorge Tolivia, Ana Navarro, Rafael Franco, Eva Martínez-Pinill. Heteromers Formed by GPR55 and Either Cannabinoid CB International journal of molecular sciences. vol 25. issue 8. 2024-04-27. PMID:38673761. |
heteromers formed by gpr55 and either cannabinoid cb multiple sclerosis (ms) is an autoimmune, inflammatory, and neurodegenerative disease of the central nervous system for which there is no cure, making it necessary to search for new treatments. |
2024-04-27 |
2024-04-29 |
Not clear |
| Livia Guadalupi, Georgia Mandolesi, Valentina Vanni, Sara Balletta, Silvia Caioli, Anto Pavlovic, Francesca De Vito, Diego Fresegna, Krizia Sanna, Laura Vitiello, Monica Nencini, Alice Tartacca, Fabrizio Mariani, Valentina Rovella, Sven Schippling, Iris Ruf, Ludovic Collin, Diego Centonze, Alessandra Musell. Pharmacological blockade of 2-AG degradation ameliorates clinical, neuroinflammatory and synaptic alterations in experimental autoimmune encephalomyelitis. Neuropharmacology. 2024-04-03. PMID:38570068. |
the endocannabinoid system (ecs) is critically involved in the pathophysiology of multiple sclerosis (ms), a neuroinflammatory and neurodegenerative disease of the central nervous system (cns). |
2024-04-03 |
2024-04-06 |
mouse |
| Kawthar Safi, Jan Sobieraj, Michał Błaszkiewicz, Joanna Żyła, Bartłomiej Salata, Tomasz Dzierżanowsk. Tetrahydrocannabinol and Cannabidiol for Pain Treatment-An Update on the Evidence. Biomedicines. vol 12. issue 2. 2024-02-24. PMID:38397910. |
the impact of cannabinoids in chronic cancer pain and in non-cancer conditions, such as multiple sclerosis and headaches, are all discussed, as well as novel techniques of administration and relevant mechanisms of action. |
2024-02-24 |
2024-02-26 |
Not clear |
| Roua A Nouh, Ahmed Kamal, Oluwaseyi Oyewole, Walaa A Abbas, Bishoy Abib, Abdelrouf Omar, Somaia T Mansour, Anwar Abdelnase. Unveiling the Potential of Cannabinoids in Multiple Sclerosis and the Dawn of Nano-Cannabinoid Medicine. Pharmaceutics. vol 16. issue 2. 2024-02-24. PMID:38399295. |
unveiling the potential of cannabinoids in multiple sclerosis and the dawn of nano-cannabinoid medicine. |
2024-02-24 |
2024-02-26 |
Not clear |
| Olivia Cresswell, Karis Blankenship, Barbara L F Kapla. Development of an in vitro peptide-stimulated T cell assay to evaluate immune effects by cannabinoid compounds. International immunopharmacology. vol 129. 2024-02-09. PMID:38335658. |
previous studies demonstrated that cannabinoids exhibit immunosuppressive effects in experimental autoimmune encephalomyelitis (eae), the animal model of multiple sclerosis (ms). |
2024-02-09 |
2024-02-12 |
Not clear |
| Fabio Arturo Iannott. Cannabinoids, Endocannabinoids, and Synthetic Cannabimimetic Molecules in Neuromuscular Disorders. International journal of molecular sciences. vol 25. issue 1. 2024-01-11. PMID:38203407. |
in this context, a significant amount of knowledge about the safety and effectiveness of cannabinoids in nmds has been obtained from studies involving patients with multiple sclerosis experiencing pain and spasticity. |
2024-01-11 |
2024-01-13 |
Not clear |
| Victor Voicu, Felix-Mircea Brehar, Corneliu Toader, Razvan-Adrian Covache-Busuioc, Antonio Daniel Corlatescu, Andrei Bordeianu, Horia Petre Costin, Bogdan-Gabriel Bratu, Luca-Andrei Glavan, Alexandru Vlad Ciure. Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy. Biomolecules. vol 13. issue 9. 2023-09-28. PMID:37759788. |
special emphasis is placed on the role of cannabinoids in neurodegenerative diseases, showcasing their potential benefits in conditions such as alzheimer's disease, parkinson's disease, huntington's disease, and multiple sclerosis. |
2023-09-28 |
2023-10-07 |
human |
| Mary K Piscura, Angela N Henderson-Redmond, Robert C Barnes, Swarup Mitra, Josée Guindon, Daniel J Morga. Mechanisms of cannabinoid tolerance. Biochemical pharmacology. 2023-06-22. PMID:37348821. |
there is evidence to support the use of cannabinoids for the treatment of chronic pain, muscle spasticity, nausea and vomiting due to chemotherapy, improving weight gain in hiv-related cachexia, emesis, sleep disorders, managing symptoms in tourette syndrome, and patient-reported muscle spasticity from multiple sclerosis. |
2023-06-22 |
2023-08-14 |
Not clear |
| S Gustavsen, A Olsson, A B Oturai, K Linnet, R Thomsen, B S Rasmussen, C F Jørgensen, A R Langkilde, P S Sorensen, F Sellebjerg, H B Søndergaar. The peripheral endocannabinoid system and its association with biomarkers of inflammation in untreated patients with multiple sclerosis. European journal of neurology. 2023-06-20. PMID:37337838. |
the peripheral endocannabinoid system and its association with biomarkers of inflammation in untreated patients with multiple sclerosis. |
2023-06-20 |
2023-08-14 |
Not clear |
| S Gustavsen, A Olsson, A B Oturai, K Linnet, R Thomsen, B S Rasmussen, C F Jørgensen, A R Langkilde, P S Sorensen, F Sellebjerg, H B Søndergaar. The peripheral endocannabinoid system and its association with biomarkers of inflammation in untreated patients with multiple sclerosis. European journal of neurology. 2023-06-20. PMID:37337838. |
the endocannabinoid system (ecs) has been found altered in patients with multiple sclerosis (ms). |
2023-06-20 |
2023-08-14 |
Not clear |
| Carmen-Adella Sirbu, Ruxandra Georgescu, Florentina Cristina Pleşa, Alina Paunescu, Monica Marilena Ţânţu, Alina Crenguţa Nicolae, Ionut Caloianu, Marian Mitric. Cannabis and Cannabinoids in Multiple Sclerosis: From Experimental Models to Clinical Practice-A Review. American journal of therapeutics. vol 30. issue 3. 2023-06-06. PMID:37278703. |
cannabis and cannabinoids in multiple sclerosis: from experimental models to clinical practice-a review. |
2023-06-06 |
2023-08-14 |
Not clear |
| Mohammed Salha, Henry Adenusi, John H Dupuis, Enrico Bodo, Bruno Botta, Iain McKenzie, Rickey Y Yada, David H Farrar, Jakob Magolan, Kun V Tian, Gregory A Chas. Bioactivity of the cannabigerol cannabinoid and its analogues - the role of 3-dimensional conformation. Organic & biomolecular chemistry. 2023-05-24. PMID:37222259. |
cannabinoids are naturally occurring bioactive compounds with the potential to help treat chronic illnesses including epilepsy, parkinson's disease, dementia and multiple sclerosis. |
2023-05-24 |
2023-08-14 |
Not clear |
| Roua A Nouh, Ahmed Kamal, Anwar Abdelnase. Cannabinoids and Multiple Sclerosis: A Critical Analysis of Therapeutic Potentials and Safety Concerns. Pharmaceutics. vol 15. issue 4. 2023-04-28. PMID:37111637. |
cannabinoids and multiple sclerosis: a critical analysis of therapeutic potentials and safety concerns. |
2023-04-28 |
2023-08-14 |
Not clear |
| Carmen Martinez-Paz, Emilio García-Cabrera, Ángel Vilches-Arena. Effectiveness and Safety of Cannabinoids as an Add-On Therapy in the Treatment of Resistant Spasticity in Multiple Sclerosis: A Systematic Review. Cannabis and cannabinoid research. 2023-04-14. PMID:37057959. |
effectiveness and safety of cannabinoids as an add-on therapy in the treatment of resistant spasticity in multiple sclerosis: a systematic review. |
2023-04-14 |
2023-08-14 |
Not clear |
| Alberto Gajofatto, Nicolò Cardobi, Francesca Gobbin, Massimiliano Calabrese, Marco Turatti, Maria Donata Benedett. Resting-state functional connectivity in multiple sclerosis patients receiving nabiximols for spasticity. BMC neurology. vol 23. issue 1. 2023-03-29. PMID:36991352. |
nabiximols (sativex®) is a cannabinoid approved for multiple sclerosis (ms)-related spasticity. |
2023-03-29 |
2023-08-14 |
Not clear |
| Bahareh Abd-Nikfarjam, Amirhossein Dolati-Somarin, Vafa Baradaran Rahimi, Vahid Reza Askar. Cannabinoids in neuroinflammatory disorders: Focusing on multiple sclerosis, Parkinsons, and Alzheimers diseases. BioFactors (Oxford, England). 2023-01-13. PMID:36637897. |
in addition, the identification of psychotropic plant cannabinoids has led to more studies regarding the cannabinoid system and its therapeutic features in the treatment and management of clinical symptoms of neuroinflammatory disorders, such as multiple sclerosis (ms), parkinsons disease (pd), and alzheimers disease (ad). |
2023-01-13 |
2023-08-14 |
Not clear |
| Alicia Sánchez-Sanz, María Posada-Ayala, Julia Sabín-Muñoz, Ismael Fernández-Miranda, Yolanda Aladro-Benito, Roberto Álvarez-Lafuente, Ana Royuela, Ruth García-Hernández, Ofir Rodríguez-De la Fuente, Julián Romero, Antonio García-Merino, Antonio José Sánchez-Lópe. Endocannabinoid levels in peripheral blood mononuclear cells of multiple sclerosis patients treated with dimethyl fumarate. Scientific reports. vol 12. issue 1. 2022-11-26. PMID:36434122. |
endocannabinoid levels in peripheral blood mononuclear cells of multiple sclerosis patients treated with dimethyl fumarate. |
2022-11-26 |
2023-08-14 |
Not clear |
| Alicia Sánchez-Sanz, María Posada-Ayala, Julia Sabín-Muñoz, Ismael Fernández-Miranda, Yolanda Aladro-Benito, Roberto Álvarez-Lafuente, Ana Royuela, Ruth García-Hernández, Ofir Rodríguez-De la Fuente, Julián Romero, Antonio García-Merino, Antonio José Sánchez-Lópe. Endocannabinoid levels in peripheral blood mononuclear cells of multiple sclerosis patients treated with dimethyl fumarate. Scientific reports. vol 12. issue 1. 2022-11-26. PMID:36434122. |
the endocannabinoid system (ecs), a signalling network with immunomodulatory properties, is a potential therapeutic target in multiple sclerosis (ms). |
2022-11-26 |
2023-08-14 |
Not clear |
| Bhasker Amatya, Fary Kha. Are cannabis and cannabinoids effective for symptomatic treatment in people with multiple sclerosis? - A Cochrane Review summary with commentary. American journal of physical medicine & rehabilitation. 2022-09-13. PMID:36099645. |
are cannabis and cannabinoids effective for symptomatic treatment in people with multiple sclerosis? |
2022-09-13 |
2023-08-14 |
Not clear |
| Piotr Przybycień, Danuta Gąsior-Perczak, Wojciech Plach. Cannabinoids and PPAR Ligands: The Future in Treatment of Polycystic Ovary Syndrome Women with Obesity and Reduced Fertility. Cells. vol 11. issue 16. 2022-08-26. PMID:36010645. |
cannabinoids (cbs) are used to treat chronic pain, chemotherapy-induced nausea and vomiting, and multiple sclerosis spasticity. |
2022-08-26 |
2023-08-14 |
human |